The launch date of Foscarbidopa/Foscarbidopa for injection is revealed

Foscarbidopa/foslevodopa for injection (foscarbidopa/foslevodopa) is a new treatment drug for the fluctuation of motor ability in adult patients with advanced Parkinson's disease (PD).

On 2024October17, AbbVie announced that the U.S. Food and Drug Administration (FDA) has officially approved its listing. This is the first subcutaneous levodopa-based 24-hour continuous infusion therapy approved by the FDA, marking an important milestone in the treatment of Parkinson's disease. Foscarbidopa for injection/The launch of Foscarbidopa for injection provides new treatment options for patients with advanced Parkinson's disease, helping to better control fluctuations in motor symptoms and improve patients' quality of life.

Except for the United States, Foscarbidopa for Injection/Foscarbidopa for Injection has not been publicly reported in other countries or regions. However, it is worth noting that starting from 2023year12month1, containingFoslevodopa and FoscarbidopaProduodopa are now available in Germany. Although Produodopa and Vyalev have different trade names, their main ingredients are the same, and they are both subcutaneous infusion therapies for patients with Parkinson's disease.

Parkinson's disease is a chronic progressive neurological disease in which patients often experience symptoms such as fluctuations in motor ability. Although traditional oral drug treatment can relieve symptoms, there are problems such as fluctuations in efficacy and obvious side effects. Foscarbidopa for Injection/The launch of Foscarbidopa for Injection provides a new treatment option for patients with advanced Parkinson's disease. Its subcutaneous 24Hourly continuous infusion can help control symptoms more stably, reduce fluctuations in drug efficacy, and improve patients' quality of life.

With the launch of foscarbidopa for injection/foscarbidopa in the United States, the drug is expected to be gradually promoted globally. In the future, we look forward to more clinical trials and studies to verify the efficacy and safety of foscarbidopa for injection/foscarbidopa, bringing more treatment options and hope to patients with Parkinson's disease.

Reference materials:https://www.vyalev.com/